At the news
? BEARISHIMPACT 7/10 8-K filed Aug 12, 2026 at 16:01 ET
Outlook Therapeutics filed an 8-K reporting preliminary cash of ~$11.2M as of June 30, 2026, confirming a going-concern risk with cash runway only into September 2026. The company also terminated its ATM prospectus supplement (though the underlying agreement remains in effect) and updated risk factors following FDA approval of LYTENAVA in July 2026. The combination of a severe cash crunch, ongoing losses, and a dilutive debt structure with mandatory redemptions starting September 2026 outweighs the positive of FDA approval, making this filing bearish.
- Preliminary cash and cash equivalents of ~$11.2M as of June 30, 2026
- Going-concern warning: cash runway only into September 2026 based on $7.7M at March 31, 2026 plus $4.2M April and $4.9M May offerings
- $19.8M principal/interest/exit fees outstanding on Atlas promissory note with 9.5% minimum interest and 7.5% exit fee
- Atlas can redeem up to $3.0M per quarter starting September 2026
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access